EU/3/18/1991: Orphan designation for the treatment of sickle cell disease
Docosahexaenoic acid ethyl ester
Table of contents
Overview
On 21 March 2018, orphan designation (EU/3/18/1991) was granted by the European Commission to TurnKey PharmaConsulting Ireland Limited, Ireland, for docosahexaenoic acid ethyl ester (also known as SC411) for the treatment of sickle cell disease.
Key facts
Active substance |
Docosahexaenoic acid ethyl ester
|
Intended use |
Treatment of sickle cell disease
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/18/1991
|
Date of designation |
21/03/2018
|
Sponsor |
Turnkey PharmaConsulting Ireland Limited |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: